ScholarLens Back to search
1994•Kitakantou igaku/Kitakantō IgakuOpen access

PROSTAGLANDIN E1 THERAPY IN PATIENTS OF CONGENITAL HEART DISEASE WITH PULMONARY ATRESIA

Takashi Kosuda, KATSUHIKO SONE, HIROSHI TABATA, Makoto Shinohara, Toshihiro Kobayashi, Tomio Kobayashi

Open full text 1 citations

Abstract

We report herein the clinical assessment of prostaglandin E1 (PGE1) therapy in congenital heart disease with pulmonary atresia. PGE1CD was administrated to 28 patients and LipoPGE1 was administrated to 20 patients. The dose of PGE1CD was initially 10 ng/kg/min and the dose of LipoPGE1 was initially 5 ng/kg/min. At the onset of infusion, the patients were 13.0±26. 3 days old in the PGE1CD group and 1.7±2.3 days old in the LipoPGE1 group.We were able to examine the PA-index in 8 cases in the LipoPGE1 group. The mean diameters of right and left pulmonary arteries in these patients increased significantly after the LipoPGE1 therapy. The PA-index also increased significantly. Side effects were observed in 46.4% of the PGE1CD group and in 30.0% of the LipoPGE1 group. In 78.5% of the PGE1CD group and 90.0% of the LipoPGE1 group, the patients survived and were able to undergo surgery.

Open-access reader

About this research paper

What this paper is about

We report herein the clinical assessment of prostaglandin E1 (PGE1) therapy in congenital heart disease with pulmonary atresia. PGE1CD was administrated to 28 patients and LipoPGE1 was administrated to 20 patients. The dose of PGE1CD was initially 10 ng/kg/min and the dose of LipoPGE1 was initially 5 ng/kg/min. At the onset of infusion, the patients were 13.0±26. 3 days old in the PGE1CD group and 1.7±2.3 days old in the LipoPGE1 group.We were able to examine the PA-index in 8 cases in the LipoPGE1 group. The mean diameters of right and left pulmonary arteries in these patients increased significantly after the LipoPGE1 therapy. The PA-index also increased significantly. Side effects were observed in 46.4% of the PGE1CD group and in 30.0% of the LipoPGE1 group. In 78.5% of the PGE1CD group and 90.0% of the LipoPGE1 group, the patients survived and were able to undergo surgery.

Why it matters

OpenAlex reports 1 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

We report herein the clinical assessment of prostaglandin E1 (PGE1) therapy in congenital heart disease with pulmonary atresia. PGE1CD was administrated to 28 patients and LipoPGE1 was administrated to 20 patients. The dose of PGE1CD was initially 10 ng/kg/min and the dose of LipoPGE1 was initially 5 ng/kg/min. At the onset of infusion, the patients were 13.0±26. 3 days old in the PGE1CD group and 1.7±2.3 days old in the LipoPGE1 group.We were able to examine the PA-index in 8 cases in the LipoPGE1 group. The mean diameters of right and left pulmonary arteries in these patients increased significantly after the LipoPGE1 therapy. The PA-index also increased significantly. Side effects were observed in 46.4% of the PGE1CD group and in 30.0% of the LipoPGE1 group. In 78.5% of the PGE1CD group and 90.0% of the LipoPGE1 group, the patients survived and were able to undergo surgery.

Key concepts: Prostaglandin E1, Medicine, Pulmonary atresia, Heart disease, Atresia, Prostaglandin, Surgery, Internal medicine

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
PROSTAGLANDIN E1 THERAPY IN PATIENTS OF CONGENITAL HEART DISEASE WITH PULMONARY ATRESIA — Research Paper | ScholarLens